Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV Ibogaine
- Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure”
- Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure”
- “Canadian Reorganization”
- “Cost Containment Initiatives”
- Algernon Pharmaceuticals Makes DMT Stroke Research Program Its Lead Asset
- Other News
- atai Pivots to IV Formulation of Ibogaine
- Seaport Therapeutics Launches with $100m Series A, Pipeline Includes ‘Prodrug of a Non-Hallucinogenic Neuroplastogen’
- Otsuka and Click Score FDA Clearance for Rejoyn, First Prescription Digital Therapeutic for A Mental Health Condition.
- Do Psilocybin Trial Participants Believe in the ‘Inner Healer’?
- LSD Microdosing Improves Sleep, According to New Publication
- “Petition for the FDA to Convene an Open Advisory Committee Meeting to Hear Concerns on MDMA-Assisted Therapy”
- In Case You Missed It
Companies, organisations and drug candidates mentioned in this Bulletin: Numinus Wellness; The Dales Report; Algernon Pharmaceuticals; AP-188; Seyltx; atai Life Sciences; IBX-210; DMX-1002; Seaport Therapeutics; Karuna; SPT-348; Otsuka; Click Therapeutics; Rejoyn; Lykos Therapeutics...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In